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Abstract 
Dental pulp stem cells (DPSC) are neural crest-derived ecto-mesenchymal stem cells that 
can relatively easily and non-invasively be isolated from the dental pulp of extracted 
postnatal and adult teeth. Accumulating evidence suggests that DPSC have great promise 
as a cellular therapy for central nervous system (CNS) and retinal injury and disease. The 
mode of action by which DPSC confer therapeutic benefit may comprise multiple pathways, 
in particular, paracrine-mediated processes which involve a wide array of secreted trophic 
factors and is increasingly regarded as the principal predominant mechanism. In this concise 
review, we present the current evidence for the use of DPSC to repair CNS damage, 
including recent findings on retinal ganglion cell neuroprotection and regeneration in optic 
nerve injury and glaucoma.  
 
 
Abbreviations: DPSC, dental pulp stem cells; CNS, central nervous system; MSC, 
mesenchymal stem cells; GFAP, glial fibrillary acidic protein; SHED, stem cells from human 
exfoliated deciduous teeth; SCAP, stem cells from the apical papilla; PDLSC, periodontal 
ligament stem cells; NTF, neurotrophic factors; RGC, retinal ganglion cells; AMD, age-
related macular degeneration; EGF, epidermal growth factor; FGF, fibroblast growth factor; 
NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin-3; 
GDNF, glial cell line-derived neurotrophic factor; VEGF, vascular endothelial growth factor; 
PDGF, platelet-derived growth factor; BMSC, bone marrow-derived mesenchymal stem 
cells; AMSC, adipose-derived mesenchymal stem cells; RGC, TBI, traumatic brain injury; 
AD, Alzheimer’s disease; PD, Parkinson’s disease; SHH, sonic hedgehog; SCI, spinal cord 
injury; RPE, retinal pigment epithelium; TON, traumatic optic neuropathy 
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Introduction 
Dental pulp, the vital inner core of teeth is a fibrous tissue containing mesenchymal 
stem/stromal cells (MSC) derived from the embryonic cranial neural crest [1]. Dental pulp 
stem cells (DPSC) are self-renewing and multipotent cells that express both MSC-like (e.g. 
CD29, CD90, CD105, CD146, CD166 and CD271) and neural stem cell-like (e.g. nestin, glial 
fibrillary acidic protein (GFAP)) phenotypic stem cell markers while being negative for 
hematopoietic markers such as CD45 [2-5]. DPSC can be readily isolated from the pulp of 
the 3rd adult molars (wisdom teeth) and expanded and stored for future use [2-4]. Dental 
stem cells can also be isolated from other discreet regions of the tooth including the dental 
follicle which surrounds developing teeth, termed dental follicle stem cells [6], the deciduous 
teeth of infants, termed SHED (stem cells from human exfoliated deciduous teeth) cells [7, 
8], the apical papilla of immature teeth, termed SCAP (stem cells from the apical papilla) [9] 
and periodontal ligament (PDLSC) [10]. Regardless of origin, dental stem cells have shown 
rapid proliferation rates and are able to differentiate along typical mesodermal cell lineages 
such as chondrogenic, adipogenic and osteogenic lineages [5-11]. Their neural crest 
lineage, expression of neuronal markers and neurotrophic factors (NTF) as well as their 
potential neurogenic differentiation capabilities have driven research into assessing their 
potential use to treat neuronal disease and injury [3, 5, 12]. 
 
The CNS encompasses the brain and spinal cord and acts as the centre of all sensory 
perception and motor output. The CNS has very limited capacity for repair and regeneration; 
thus injury to this region is severely and permanently debilitating as damaged/axotomised 
neurons undergo cell death and are not replaced and most transected CNS axons do not 
regenerate [13]. Degeneration of injured CNS axons is attributed to the cessation of 
retrograde axonal transport of pro-survival NTF from the previously innervated targets. 
Functional loss can also be attributed to the loss of glia, particularly myelinating 
oligodendrocytes; however in most cases their loss is secondary to the damage/loss of 
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neurons. The retina is part of the CNS and suffers from the same limited capacity for repair. 
Injury to the retina can take multiple forms from photoreceptor/retinal ganglion cell (RGC) 
loss (AMD (age-related macular degeneration), glaucoma) to axonal transection (traumatic 
optic neuropathy) [13]. Stem cells may offer a suitable therapeutic approach to repair CNS, 
either by acting as a source of new neurons to integrate into neuronal tissue and replace 
those that have been lost (cell replacement), or by acting as a source of trophic factors to 
promote regeneration and survival of endogenous neurons (paracrine-mediated therapy; 
Figure 1). Although neural stem cells have been identified in the postnatal and adult brain, 
their role in endogenous functional CNS repair appears limited and isolation and 
amplification of these cells is met with various technical hurdles and ethical concerns. 
Embryonic and induced-pluripotent stem cells have also demonstrated potential, particularly 
for cell replacement, with the latter overcoming many of the ethical concerns affecting the 
former. However, new emerging therapies utilizing postnatal or adult MSCs have gained 
increasing attention demonstrating promising potential for neural tissue repair and 
regeneration, in particular through stimulation of endogenous repair processes by secreted 
paracrine factors [14-16]. 
 
In the following concise review we focus on the therapeutic potential of DPSC (also regarded 
an ecto-MSC due to its neural crest origin), and where relevant, in comparison to other more 
widely used MSC types to underscore the potential advantage of DPSC as a neuroprotective 
and neuroregenerative cell therapy for patients after CNS trauma [16, 17]. We will briefly 
discuss the neurogenic and neurotrophic properties of DPSC, followed by summarising the 
application of DPSC for brain and spinal cord repair, and in conclusion our recent work on 
the use of DPSC for retinal neuronal regeneration.  
 
The case for DPSC as neuronal cell therapy 
Neurogenic differentiation potential of DPSC  
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The classical application for stem cells is based on their ability to proliferate and differentiate 
into new specialised cells to facilitate replacement and regeneration of tissues. In particular, 
the neural crest origin and nestin-expression of DPSC has supported the notion that these 
cells may be amenable to differentiation into functional neurons and hence are suitable as 
source of replacement cells for injured neuronal cells [1-4, 16]. DPSC have been reported to 
differentiate into neurons when treated with typical neurogenic supplements such as 
epidermal growth factor (EGF), basic fibroblast growth factor (FGF) and retinoic acid [18] as 
well as forskolin [19], expressing neuronal specific neurofilament medium- and heavy-chain 
peptides, generate sodium currents [18] as well as voltage-dependant sodium and 
potassium channels. Utilizing these factors, pre-differentiated DPSC survived and integrated 
into the brain parenchyma after transplantation into the cerebrospinal fluid of rats following a 
cortical lesion and continued to remain function for up to 4 weeks [20]. DPSC-derived 
neurons maintained their expression of mature neuronal markers (such as NeuN), voltage-
gated sodium channels and delayed rectifier potassium channels [20]. However, a separate 
study contradicted these claims, suggesting that DPSC may differentiate into neuronal 
precursor cells based on expression of typical phenotypic markers, but was unable to fully 
differentiate into mature neurons lacking the ability to generate action potentials [21]. It 
should also be remarked that MSC/DSPC represent relative heterogeneous cell populations 
with the possibility that specific subsets of cells may display distinct differentiation profiles, 
including cell types with increased neurogenic capacity [22]. In conclusion, the identity of 
neurogenic MSC/DPSC and their differentiation potential needs further clarification. Although 
DPSC seem to lag behind the impressive advances seen with embryonic and induced 
pluripotent stem cell research (reviewed in [16]), enabling differentiation into not only 
functional but also specialised neurons including all those that make up the retina [23, 24], 
the therapeutic prospects of these dental stem cells as neurogenic support for nerve 
regeneration may be substantial. 
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Neurotrophic properties of DPSC  
It is now widely recognised that the predominant therapeutic action by MSC is paracrine-
mediated through the secretion of trophic and anti-inflammatory factors. Various studies 
have demonstrated the significant neurotrophic expression and secretion of DPSC 
encompassing nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), glial cell-line derived neurotrophic factor (GDNF), vascular endothelial 
growth factor (VEGF) and platelet-derived neurotrophic factor (PDGF) [12, 25-27]. These 
NTF have varying degrees of efficacy and importance with NGF being predominantly 
axogenic/neuritogenic while BDNF and PDGF being more essential for neuroprotection [26]. 
Our recent work confirmed that a range of DPSC neurotrophic genes and factors, including 
NGF, BDNF, NT-3 and VEGF with GDNF and PDGF, exceeded the levels expressed and 
secreted by other MSC types such as bone marrow (BMSC) and adipose-derived MSC 
(AMSC) [25, 26]. Along with driving axon regeneration, DPSC derived factors have also 
been reported to mediate axon guidance, shown elegantly following transplantation into a 
developing chick embryo. Although these results were done in the trigeminal nerve, a 
component of the peripheral rather than CNS, authors demonstrated that DPSC-derived 
CXCL12 was an important factor in guiding axons along the trajectory of axonal growth. 
These results suggest a potential for DPSC to promote and guide the regeneration of injured 
CNS axons to their necessary targets [28]. In contrast to these fascinating findings, 
embryonic and induced pluripotent stem cells lack evidence for any significant paracrine 
support [16]. Therefore, MSC and particular DPSC represent an ideal cell type for indirect 
repair and protection of CNS injury sites 
 
DPSC for repair of brain injury: potential treatment for TBI/Stroke  
An effective stem cell-based treatment for brain injuries such as traumatic brain injury (TBI) 
and stroke would require cells that adequately graft, integrate and remain within the brain. 
DPSC transplanted into healthy uninjured brain stimulated migration and proliferation of 
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endogenous neural cells and also increases the expression of NTF such as ciliary 
neurotrophic factor, VEGF and FGF within the graft site [29]. Although the graft itself was 
short lived, these results underscore the potential of DPSC to modulate brain tissue 
indirectly through paracrine-mediated mechanisms. 
 
Stroke is a life threatening cerebrovascular condition resulting in ischaemic damage to the 
brain and remains the second leading cause of death. Intracerebral transplantation of DPSC 
in a rodent model of focal cerebral ischemia led to an improvement in forelimb sensorimotor 
function, despite only 2% of transplanted DPSC migrating and engrafting into the lesion site 
4 weeks after transplantation [30]. DPSC predominately differentiated into glia as identified 
by GFAP (glial fibrilliary acidic protein) expression rather than neurons (neuronal specific 
enolase marker), suggesting that the functional benefit elicited by DPSC was indirect, 
paracrine-mediated as opposed to directly replacing neurons that have been lost due to 
ischaemic damage [30]. The fact that the majority of DPSC-derived cells were rapidly 
cleared despite the improvement in function corroborates the theory that DPSC promote 
functional regeneration of endogenous CNS tissue. In another report, DPSC transplanted 
into the ventricles of animals with hypoxic-ischaemic brain damage promoted the survival 
and formation of neuronal and glial cells while improving functional performance as 
assessed by a variety of behavioural tests [31]. Although these results implied that that 
DPSC may have formed new cells to replace the damaged neurons, considering the low 
survival rate of the grafted cells, it is plausible to assume that the achieved neuroprotection 
was due to indirect endogenous stimulation and protection of host neurons and glia [31]. 
Using SHED cells in a model of hypoxic-ischaemic injury of the brain in mice, it was found 
that SHED transplantation improved neurological function as measured by behavioural foot-
fault testing whilst preventing tissue atrophy and reducing the number of endogenous 
apoptotic cells [32]. Interestingly, differentiation into neuron and glia was reportedly absent, 
suggesting the neuroprotective benefits and functional improvement were caused by 
paracrine-mediated processes. 
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One study using DPSC pre-differentiated with EGF, bFGF and retinoic acid into neuron-like 
cells described that, after transplantation into the cerebrospinal fluid of rats with a TBI, 
DPSC-derived cells migrated into various brain regions including the lesion site and adopted 
a neuronal phenotype expressing functional sodium/potassium currents [20]. Taken 
together, we feel that these findings underscore the capability of DPSC to migrate and 
survive within a CNS lesion site offering a suitable therapy for TBI either through pre-
differentiation and replacement of lost neurons or as paracrine-mediated supporters of 
endogenous neuronal survival and axonal sprouting vehicles. 
 
DPSC have also been considered for neurodegenerative diseases such as Alzheimer’s (AD) 
and Parkinson’s diseases (PD), which are characterised by the gradual and permanent loss 
of neurons. Using in vitro models of AD/PD, co-culture of DPSC with hippocampal and 
mesencephalic neurons treated with amyloid beta peptide or 6-hydroxydopamine (6-OHDA) 
significantly reduced toxicity and death of neurons, which could be related to the expression 
of several NTF including NGF, GDNF and BDNF by DPSC [33]. DPSC also appeared to 
differentiate into dopaminergic neurons in vitro after treatment with sonic hedgehog (SHH), 
FGF9, GDNF and forskolin, although whether they have the ability to maintain this 
phenotype and replace lost dopaminergic neurons in PD in vivo has not yet been established 
and warrants further research [34]. 
 
Potential DPSC treatment for SCI 
Spinal cord injury (SCI) is a severe debilitating condition that results in permanent partial or 
complete loss of sensation, paralysis of lower extremities and in severe cases, upper 
extremities and respiratory arrest. In a seminal study, DPSC were tested for their efficacy as 
a treatment for SCI in comparison with BMSC and AMSC [12]. DPSC were shown to 
promote in vitro neuritogenesis over an inhibitory medium containing chondroitin sulphate 
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proteoglycans and myelin-associated glycoprotein, underlying their potential as a paracrine-
based therapy for promoting axon regeneration through the surrounding inhibitory factors of 
the spinal cord lesion site. After transplantation into SCI sites, DPSC did not differentiate into 
neurons but did promote the survival of endogenous neurons and glia within and around the 
lesion site [12]. Remarkably, surviving corticospinal tract axons regenerated over significant 
distances across the lesion site and biotinylated dextran amine (BDA)-labelling which 
confirmed not only extensive axon regeneration into the scar of the lesion site but also 
regeneration beyond the epicentre and into the distal cord. The substantial axon 
regeneration by DPSC correlated with improved results in the functional hind-limb 
locomotory tests, and particularly noteworthy, was significantly more than in animals 
receiving BMSC or AMSC transplants. Although this study primarily supported DPSC 
therapeutic potential through paracrine-mediated mechanisms, oligodendrocyte 
differentiation and subsequent remyelination of regenerated axons may have indirectly 
contributed to the functional restitution in these animals, presenting a potentially secondary 
mechanism. Further studies have looked into the potential benefit of glia-derived DPSC by 
inducing them to differentiate into Schwann-like glial cells which secrete greater titres of NTF 
compared to undifferentiated DPSC. In vitro, these Schwann-like cells promoted greater 
regeneration of dorsal root ganglion cell (from the spinal cord) neurites compared to DPSC 
[35]. Corroborating these results, SHED cells, pre-differentiated down a neural lineage 
before transplantation into a SCI site also improved locomotion in rats after SCI, underlining 
the potential of dental stem cells as promising cell therapy for CNS repair and regeneration 
[36].  
 
DPSC treatment for retinal repair in ocular injury or disease 
The retina is a complex structure composed of three layers of interconnected neurons, 
photoreceptors, bipolar cells and RGC laying atop the retinal pigment epithelium (RPE) and 
also populated by supportive amacrine and horizontal cells. The retina and optic nerve, 
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formed during development as an outgrowth of the brain [13], is an integral part of the CNS. 
Ocular disease can arise from a degenerative chronic abnormality such as AMD 
characterised by a slow progressive loss of retinal photoreceptor and RPE cells. On the 
other hand, glaucoma entails degeneration of RGC due to compression of the optic nerve, 
typically (but not necessarily) due to elevated intraocular pressure. Traumatic optic 
neuropathy (TON) is rather analogous to SCI and often involves damage to the optic nerve 
leading to a sudden acute loss of retinal cells and their axons and an immediate loss of 
visual function. 
 
Previous proof-of-principle studies have shown that primary photoreceptors transplanted into 
the eye integrate into the outer nuclear layer of the retina and restore visual function [32]. 
However obtaining large numbers of photoreceptors from young donor eyes is clinically not 
feasible [37, 38] and thus an alternative therapeutic strategy for AMD is needed, ideally a 
stem cell source which is easily accessible and can be expanded and differentiated into 
photoreceptor cells. The usefulness of DPSC as potential treatment for AMD is not yet 
known. It was reported recently that DPSC can be induced to differentiate into a 
photoreceptor phenotype after exposure to conditioned medium from injured organotypic 
retinal cultures [39]. These DPSC-derived photoreceptors express the phenotypic marker 
rhodopsin but their functional activity has not yet been confirmed. 
 
DPSC have also recently been suggested to have the potential to differentiate into RGC-like 
cells [40]. When treated with FGF2 and SHH while seeded on a 3-dimensional fibrin 
hydrogel, DPSC showed phenotypic signs of RGC differentiation including the expression of 
RGC associated genes/proteins such as Brn3b; however, again it is still unclear whether 
these cultivated cells are bona fide RGC and functional that can be used to successfully 
integrate into the retina to restore vision. Another important consideration is that DPSC-
derived RGC would need to regenerate an axon along the complete length of the optic nerve 
before it would be functional, which has not been achieved as yet [13] 
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Recent studies explored the possibility of MSC-mediated retinal repair through paracrine-
mediated mechanisms [41]. RGC death is mostly instigated by the lack of retrograde supply 
of essential survival factors (i.e. NTF), and experimental treatments with recombinant NTF 
have demonstrated neuroprotective efficacy, albeit in a transient and short-lived fashion [13]. 
As MSC/DPSC have relatively high expression of a range of NTF, we started to investigate 
their RGC neuroprotective effects in co-cultures with axotomised, injured primary rat RGC in 
a transwell system whereby the two cell populations were separated by a semi-permeable 
membrane [25, 26]. DPSC promoted significant survival of cultured RGC and regeneration of 
their neurites (Fig. 2A, B), an effect that was largely dependent on NTF secretion since 
neuroprotection/pro-regeneration was abolished when specific fusion protein inhibitors to 
NTF-receptors are added to the cultures.  
 
We next tested the paracrine-mediated benefits by transplanting them into the vitreous of 
animals following an optic nerve crush (see also Fig. 1). Direct delivery of stem cells has 
been shown to be required, particularly as the vitreous lies adjacent to the retina and thus 
MSC-derived trophic factors will be within the RGC microenvironment. Systemic delivery 
(into peripheral blood) of BMSC failing to migrate into the retina and providing no therapeutic 
benefit, as opposed to when delivered locally into the vitreous [41]. Following transplantation 
into the vitreous, DPSC survive for the 3 weeks and promote survival of approximately 40% 
of RGC (Fig. 2C, D) with a significant increase in both regeneration (Fig. 2E-H) of their 
axons and dissolution of scar within the lesion site [25]. The relatively pronounced longevity 
of transplanted intravitreal DPSC is similar to other MSC and is likely due to the 
immunoprivileged environment of the eye, immunosuppressive properties of the MSC and 
the constrained nature of the vitreous preventing cellular migration [16], lending support to 
the potential for DPSC/MSC to act as a long-term therapy. The neuroprotective and 
axogenic effects elicited by the transplanted DPSC are significantly more pronounced than 
after BMSC transplantation, further emphasising the potential of DPSC. Recently, we 
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investigated the potential of human DPSC in an animal model of glaucoma in which 
intraocular pressure is elevated leading to a slow progressive loss of RGC [42]. We 
delivered human-derived DPSC into the vitreous and recorded both the number of surviving 
RGC and their electrical activity by electroretinography, which is indicative of their function. 
DPSC not only protected RGC from death but also preserved visual function significantly 
compared to both untreated eyes and eyes treated with BMSC/AMSC for up to 35 days. 
Studies confirming their therapeutic efficacy at longer time points have yet to be conducted. 
This is the first time DPSC have been tested in a glaucomatous model and the demonstrated 
efficacy has important implications considering the ongoing clinical trials using BMSC to treat 
various ocular diseases [16]. 
 
Future work (and challenges) 
Despite the recent and exciting advances in the field, challenges remain before DPSC are 
accepted as a clinical therapeutic for CNS disease. Still little is known about the precise 
mechanisms of action of DPSC and the role of the host environment in the endogenous 
repair in response to DPSC/MSC therapy. The MSC/DPSC secretome is a complex mixture 
of bioactive factors and further knowledge is needed as to which specific factors are key for 
therapeutic and other effects, including possible anti-inflammatory and angiogenic reactions. 
Thus further research may facilitate development of combinatorial stem cell-based therapies 
or cell-free approaches involving purified secretome fractions or exosomes. Moreover, 
although a large number of studies suggest that the mechanism is predominantly paracrine-
mediated, a role of DPSC differentiation into neurons and glia cannot be fully excluded. 
Indeed the disparity between the successes of DPSC differentiation in vitro and lack thereof 
in vivo suggests that the host environment plays a significant role. Injured neurological tissue 
presents a vastly different environment to the carefully controlled in vitro setting and studies 
on what factors may be preventing in vivo differentiation may greatly improve the potential of 
cell replacement strategies. Equally, the limiting factor for successful differentiation may be a 
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lack of migration of transplanted DPSC to the injured microenvironment. DPSC migrate to 
areas of tooth injury to replace lost cells and identification of the specific chemokines and 
receptors responsible may provide a potential therapeutic adjunct to cell replacement 
therapies [43]. Indeed some factors have already been identified and include stromal cell-
derived factor 1α, granulocyte-colony stimulating factor and FGF2 [43] with the former 
having shown efficacy in vivo [44]. 
 
For clinical translation, it is of paramount importance to address risk and safety issues as 
well as standardisation and optimisation of the isolation, culture and cryostorage conditions 
to meet regulatory requirements using DPSC isolated from extracted human teeth. The 
variability in NTF secretion by DPSC between different donors [12, 25, 26] may present a 
formidable problem to the standardisation process and cellular treatments may be required 
from a pool of mixed donors or as highlighted before, cell-free approaches utilising the MSC 
secretome, to attain a consistent therapeutic efficacy. An important question to address is 
what happens with the DPSC on a long-term basis following cell transplantation, i.e. what is 
the fate and distribution of the cells (within the vitreous of) the eye. Noteworthy, clinical trials 
have already begun to address safety issues for MSC transplantation in the eye [16]. 
Additional work should also include the development of suitable cell delivery systems such 
as using encapsulated cells within a semi-permeable biomaterial that will preserve the 
paracrine-mediated effects whilst limiting the risk of uncontrolled migration/proliferation [45, 
46].  
 
Another issue is the correct dosing of the stem cells to ensure maximum efficacy. For 
example, transplantation of BMSC into the vitreous of TON animals demonstrated that the 
extent of axon regeneration increases with increased dosing of the BMSC transplants [47]. 
Further work is also warranted to optimise NTF production by DPSC for example by altering 
the pre-culture conditions to prime and/or pre-differentiate the cells. Indeed, a recent study 
elegantly demonstrated that following pre-differentiation into Schwann-like glial cells, the 
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DPSC secreted significantly increased levels of NTF and were able to further stimulate 
neurite outgrowth in an in vitro dorsal root ganglion injury model of SCI as compared with 
non-differentiated cells [35]. 
 
Conclusions 
DPSC possess great potential in the treatment of traumatic and degenerative neurological 
conditions, the paramount mechanism of action after transplantation is probably paracrine-
mediated, with secreted NTF orchestrating sustained neuronal survival, axon regeneration 
and functional restoration and preservation. Cell differentiation may possibly play a role, in 
particular into glial-like cells which then may function either as a source of NTF or as 
supporting/remyelinating cells. The differentiation of DPSC into functional neurons is still 
contentious with the majority of studies restricted to in vitro scenarios whereas those 
transplanting DPSC-derived neural cells in vivo have yet to be definitively shown to replace 
and restore damaged neuronal circuits. DPSC have only been a focus of research for a 
relatively short period of time and as such, no clinical trials have been conducted to measure 
clinical efficacy. However, considering the substantial therapeutic potential of these cells, we 
anticipate a rapid increase in research into this area and predict that DPSC-based clinical 
trials will become reality in the not too far away future. 
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Figure 1: Schematic diagram demonstrating the application of dental stem cells in 
neural retinal repair. Dental stem cells occupy several discrete region of the tooth and 
surrounding tissue, of which, DPSC are found within the adult pulp. Isolation of DPSC from 
extracted adult teeth via relatively easy and non-invasive procedures; subsequent culture of 
DPSC allows expansion and potential manipulation (e.g. stimulation or pre-differentiation by 
defined factors) prior to transplantation. Following transplantation, DPSC may act either by 
replacing lost neurons via integration and differentiation into the affected tissue (A) and/or, 
supporting/promoting the endogenous regeneration of injured tissue through the secretion of 
multifiunctional active diffusible growth factors (e.g.NTFs). 
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Figure 2: The paracrine-mediated effects of DPSC on injured CNS neurons (RGC).  
A-B: Injured βIII-tubulin+ adult rat RGC co-cultured in a transwell with human DPSC (A) have 
significantly increased survival and regeneration of their neurites compared to co-culture with 
control cells (dead DPSC/fibroblasts (B).  
C-H: Transplanted into the vitreous of rats, DPSC elicit a significant neuroprotective effect on 
Brn3a+ RGC (C) after optic nerne crush injury (ONC) and also strong activation in supportive 
Müller glia compared to animals receiving control cells (D). In the same animals, intravitreally 
transplanted DPSC promoted significant regeneration of GAP-43+ RGC axons in the optic 
nerve at both the crush site (E) and 2mm distal to the crush site (G) in compared to control 
animals (F, H). Scale bars represent 50µm (A-D), 100µm (E, F) and 200µm (G, H). 
(Adapted and extended from Mead B, Logan A, Berry M, Leadbeater W, Scheven BA, 
Neural Regen Res. 9: 577–578, 2014; with permission of Neural Regeneration Research) 
 
 
 
